207 related articles for article (PubMed ID: 38162389)
1. Disulfidptosis-Associated lncRNAs are Potential Biomarkers for Predicting Immune Response and Prognosis Within Individuals Diagnosed with Hepatocellular Carcinoma.
Wei Q; Hou YC; Mao FF; Feng JK; Wang X; Cheng SQ
Hepat Med; 2023; 15():249-264. PubMed ID: 38162389
[TBL] [Abstract][Full Text] [Related]
2. Constructed Risk Prognosis Model Associated with Disulfidptosis lncRNAs in HCC.
Jia X; Wang Y; Yang Y; Fu Y; Liu Y
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139458
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
4. Integrated Bioinformatics and Experimental Validation to Identify a Disulfidptosis-Related lncRNA Model for Prognostic Prediction in Papillary Renal Cell Carcinoma.
Zhu Y; Jin X; Liu J
Comb Chem High Throughput Screen; 2024 Apr; ():. PubMed ID: 38639274
[TBL] [Abstract][Full Text] [Related]
5. Investigating the prognostic role of lncRNAs associated with disulfidptosis-related genes in clear cell renal cell carcinoma.
Sun Z; Wang J; Fan Z; Yang Y; Meng X; Ma Z; Niu J; Guo R; Tran LJ; Zhang J; Jiang T; Liu Y; Yang Q; Ma B
J Gene Med; 2024 Jan; 26(1):e3608. PubMed ID: 37897262
[TBL] [Abstract][Full Text] [Related]
6. A novel disulfidptosis-related lncRNA signature for predicting prognosis and potential targeted therapy in hepatocellular carcinoma.
Zhang H; Wang J; Yang M
Medicine (Baltimore); 2024 Jan; 103(4):e36513. PubMed ID: 38277541
[TBL] [Abstract][Full Text] [Related]
7. A novel disulfidptosis-related lncRNAs signature for predicting survival and immune response in hepatocellular carcinoma.
Guo Z; Xie Y; Zhang L; Liu S; Jiang W
Aging (Albany NY); 2024 Jan; 16(1):267-284. PubMed ID: 38180745
[TBL] [Abstract][Full Text] [Related]
8. Machine learning-based disulfidptosis-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity in hepatocellular carcinoma.
Pu L; Sun Y; Pu C; Zhang X; Wang D; Liu X; Guo P; Wang B; Xue L; Sun P
Sci Rep; 2024 Feb; 14(1):4354. PubMed ID: 38388539
[TBL] [Abstract][Full Text] [Related]
9. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
10. Predicting colorectal cancer prognosis based on long noncoding RNAs of disulfidptosis genes.
Wang KL; Chen KD; Tang WW; Chen ZP; Wang YJ; Shi GP; Chen YG
World J Clin Oncol; 2024 Jan; 15(1):89-114. PubMed ID: 38292658
[TBL] [Abstract][Full Text] [Related]
11. Unlocking the future of hepatocellular carcinoma treatment: A comprehensive analysis of disulfidptosis-related lncRNAs for prognosis and drug screening.
Wang H; Wang W
Open Med (Wars); 2024; 19(1):20240919. PubMed ID: 38584823
[TBL] [Abstract][Full Text] [Related]
12. Integrating bioinformatics and experimental validation to unveil disulfidptosis-related lncRNAs as prognostic biomarker and therapeutic target in hepatocellular carcinoma.
Xu L; Chen S; Li Q; Chen X; Xu Y; Zhou Y; Li J; Guo Z; Xing J; Chen D
Cancer Cell Int; 2024 Jan; 24(1):30. PubMed ID: 38218909
[TBL] [Abstract][Full Text] [Related]
13. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer.
Xing F; Qin Y; Xu J; Wang W; Zhang B
Mol Biotechnol; 2023 Sep; ():. PubMed ID: 37733182
[TBL] [Abstract][Full Text] [Related]
14. Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma.
Wang W; Ye Y; Zhang X; Ye X; Liu C; Bao L
Front Mol Biosci; 2022; 9():937979. PubMed ID: 35911976
[No Abstract] [Full Text] [Related]
15. Establishment of a prognostic risk prediction model incorporating disulfidptosis-related lncRNA for patients with prostate cancer.
Mulati Y; Lai C; Luo J; Hu J; Xu X; Kong D; Xiao Y; Liu C; Xu K
BMC Cancer; 2024 Jan; 24(1):44. PubMed ID: 38191330
[TBL] [Abstract][Full Text] [Related]
16. Disulfidptosis-Related lncRNA for the Establishment of Novel Prognostic Signature and Therapeutic Response Prediction to Endometrial Cancer.
Shi S; Tang X; Liu H
Reprod Sci; 2024 Mar; 31(3):811-822. PubMed ID: 37880552
[TBL] [Abstract][Full Text] [Related]
17. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
18. A disulfidptosis-related lncRNA index predicting prognosis and the tumor microenvironment in colorectal cancer.
Xiao L; Yin W; Chen X; Zhang X; Zhang C; Yu Z; Lü M
Sci Rep; 2023 Nov; 13(1):20135. PubMed ID: 37978247
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Analysis of Disulfidptosis-Related LncRNAs in Molecular Classification, Immune Microenvironment Characterization and Prognosis of Gastric Cancer.
Kang K; Li X; Peng Y; Zhou Y
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137387
[TBL] [Abstract][Full Text] [Related]
20. Prognosis and chemotherapy drug sensitivity in liver hepatocellular carcinoma through a disulfidptosis-related lncRNA signature.
Chen C; Wang C; Li Y; Jiang S; Yu N; Zhou G
Sci Rep; 2024 Mar; 14(1):7157. PubMed ID: 38531953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
